智通财经APP获悉，默沙东(MRK.US)的预防性抗体疗法Enflonsia已获得美国FDA批准，旨在保护婴儿免受呼吸道合胞病毒(RSV)的感染。目前这个市场由赛诺菲(SNY.US)和阿斯利康(AZN.US)开发的RSV预防疫苗Beyfortus主导 ...

这次默沙东获批的Enflonsia，其实并非疫苗，而是一种预防性抗体疗法。它通过给婴儿注射抗体，来帮助婴儿抵抗RSV病毒的侵袭。与其他RSV预防药物相比，Enflonsia最大的特点之一，就是无论婴儿的体重如何，都使用相同的105毫克剂量。 这对于医护人员来说，无疑简化了操作流程，也降低了出错的风险。

默沙东 (MRK.US)的预防性抗体疗法Enflonsia已获得美国FDA批准，旨在保护婴儿免受呼吸道合胞病毒 (RSV)的感染。目前这个市场由赛诺菲 (SNY.US)和阿斯利康 (AZN.US)开发的RSV预防疫苗Beyfortus主导。

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

赛诺菲 （ 纳斯达克 代码：SNY）宣布将提前于2025-2026呼吸道合胞病毒（RSV）季启动Beyfortus（尼塞维单抗）的配送工作。免疫接种将在初秋开始，这些提前的发货为医疗保健提供者提供了信心以支持他们的工作。

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Investing.com -- 瑞典孤儿生物制药 (Swedish Orphan Biovitrum) (STO:SOBI)股价今日下跌4%，此前美国食品药品监督管理局 (FDA)批准了默沙东集团的呼吸道合胞病毒 (RSV)疫苗Enflonsia ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...